Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT: NCT05637801 · ACTIVE_NOT_RECRUITING

NCT IDNCT05637801
StatusACTIVE_NOT_RECRUITING
Start Date2022-12-13
Completion2026-07

Brief Summary

This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device, Spectris™ AD, for 60 minutes daily for approximately 12 months. Efficacy will be measured using the Integrated Alzheimer's Disease Mini-Mental State Exam (MMSE) Activities of Daily Living (ADCS-ADL) Rating Scale (iADMARS).

Frequently Asked Questions

What is A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)?

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) is a clinical trial registered under NCT05637801. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05637801?

The current status of NCT05637801 (A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)) is: ACTIVE_NOT_RECRUITING.

When did A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) start?

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) started on 2022-12-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.